Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Evaluation Of Soluble Mesothelin-related Peptide As A Diagnostic Marker Of Malignant Pleural Mesothelioma Effusions: Its Contribution To Cytology

P. Canessa, M. C. Franceschini, P. Ferro, E. Battolla, P. Dessanti, C. Manta, M. Sivori, R. Pezzi, V. Fontana, F. Fedeli, M. Pistillo, Silvio Roncella
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Soluble mesothelin-related peptide (SMRP) is regarded as an FDA approved biomarker for the diagnosis and monitoring of pleural malignant mesothelioma (MPM). We detected the SMRP levels in pleural effusions (PE) by means of an ELISA and analyzed their diagnostic relevance to differentiate MPM from benign pathology and from non-MPM pleural metastasis. Comparison with cytology in MPM-PE was also performed. We found that SMRP detection in MPM-PE can help the diagnosis of MPM and provide additional diagnostic value to cytology. We concluded that SMRP test may be incorporated into clinical practice of PE from patients suspicious for MPM.
This paper references
10.1164/AJRCCM-CONFERENCE.2012.185.1_MEETINGABSTRACTS.A1575
Clinical Significance Of Pleural Effusion Mesothelin In Malignant Pleural Mesothelioma
S. Yamada (2012)
Puntoni R. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer
A Cristaudo (2007)
10.1198/tech.2005.s278
The Statistical Evaluation of Medical Tests for Classification and Prediction
M. Pepe (2003)
Malignant pleural effusion , current and evolving approaches for its diagnosis andmanagement
S Neragi-Miandoab (2006)
10.1097/01.MP.0000056981.16578.C3
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
10.1378/chest.08-2665
Malignant pleural mesothelioma: an update on biomarkers and treatment.
M. Ray (2009)
10.1007/BF03256303
Biomarkers for Malignant Pleural Mesothelioma
L. Greillier (2012)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1378/CHEST.111.1.106
The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.
A. Renshaw (1997)
10.1016/j.ejcts.2007.09.044
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
10.1097/JTO.0b013e318187491c
Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung Cancer
J. Schneider (2008)
Il registro nazionale dei mesoteliomi: risultati, interpretazione, commento ai dati. Il registro Nazionale dei Mesoteliomi. Istituto Superiore per la prevenzione e la sicurezza del la
A Marinaccio (2001)
10.1016/J.CCM.2005.12.002
The undiagnosed pleural effusion.
R. Light (2006)
10.1136/thx.2006.068114
Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma
J. Creaney (2007)
10.1016/S1010-7940(02)00273-7
The management of malignant pleural mesothelioma; single centre experience in 10 years.
T. Aziz (2002)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
10.1016/J.LUNGCAN.2006.04.016
Malignant pleural effusion, current and evolving approaches for its diagnosis and management.
S. Neragi-Miandoab (2006)
10.1158/1078-0432.CCR-10-1929
Serum Soluble Mesothelin Concentrations in Malignant Pleural Mesothelioma: Relationship to Tumor Volume, Clinical Stage and Changes in Tumor Burden
J. Creaney (2010)
10.4081/MONALDI.2009.374
Clinical utility of diagnostic markers for malignant pleural mesothelioma.
B. Grigoriu (2009)
10.1200/JCO.2009.26.9944
Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant mesothelioma.
P. Wheatley-Price (2010)
10.1016/S0895-4356(03)00177-X
The diagnostic odds ratio: a single indicator of test performance.
A. S. Glas (2003)
10.1073/PNAS.93.1.136
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.
K. Chang (1996)
10.1164/rccm.200811-1729OC
Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.
H. E. Davies (2009)
10.1016/j.rmed.2009.05.017
Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis.
Ling Luo (2010)
10.1097/PDM.0b013e3181ba6c78
Diagnosis and Origin Determination of Malignant Pleural Effusions Through the Use of the Breast Cancer Marker Human Mammaglobin
S. Roncella (2010)
10.1097/00000478-199203000-00006
Monoclonal Antibody K1 Reacts With Epithelial Mesothelioma but not With Lung Adenocarcinoma
K. Chang (1992)
10.1016/J.ATHORACSUR.2007.07.042
Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
H. Pass (2008)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
Soluble mesothelinrelated peptides in the diagnosis of malignant pleural mesothelioma
A Scherpereel (2006)
10.1016/j.medcli.2008.11.047
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
C. Alemán (2009)
10.1158/1078-0432.CCR-07-0629
Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer
A. Cristaudo (2007)
10.2165/1250444-200812060-00004
Biomarkers for malignant pleural mesothelioma: current status.
L. Greillier (2008)
ReNaM Working Group. Il registro nazionale dei mesoteliomi: risultati, interpretazione, commento ai dati
A Marinaccio (2001)
10.1016/J.EJCA.2005.04.047
Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002).
V. Gennaro (2005)
10.1373/CLINCHEM.2006.079327
MESOMARK: a potential test for malignant pleural mesothelioma.
H. L. Beyer (2007)
10.1002/dc.21303
The sensitivity of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma
E. Rakha (2010)



This paper is referenced by
10.1097/MD.0000000000014979
Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma
Ruiyue Gao (2019)
10.1007/s12032-013-0543-6
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
R. Filiberti (2013)
Development of more precise and efficient antibodies for cancer targeting : membrane associated form specific anti-mesothelin antibodies and CAR as an example
K. Asgarov (2016)
10.1080/19420862.2017.1288770
A new anti-mesothelin antibody targets selectively the membrane-associated form
K. Asgarov (2017)
10.4172/2153-0602.S2-001
Exploration of Biomarkers for Asbestos Exposure and Occurrence of Malignant Mesothelioma Based on the Immunological Effects of Asbestos
H. Matsuzaki (2013)
10.1007/s12032-013-0649-x
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report
P. Canessa (2013)
10.1093/carcin/bgz103
Biomarkers for malignant pleural mesothelioma: a meta-analysis.
Christina Gillezeau (2019)
Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
M. C. Franceschini (2014)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA
Rosa FilibertiStefano (2013)
10.1371/journal.pone.0185850
Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center
Takehiro Otoshi (2017)
10.21873/anticanres.13719
Determination of Mesothelin Levels in Pleural Effusion Does Not Help Predict Survival of Patients With Malignant Pleural Mesothelioma
V. Fontana (2019)
10.1016/J.EHMC.2013.02.001
Diagnosis of Pleural Effusions
J. M. Porcel (2013)
10.1016/j.chest.2016.12.004
Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment
J. Creaney (2017)
10.1186/s12931-017-0546-5
CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives
L. Cortes-Dericks (2017)
10.1136/bmjopen-2013-004145
Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
Ai Cui (2014)
Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report
Pier Aldo (2013)
10.2217/bmm-2018-0285
Fibulin-3 as biomarker of malignant mesothelioma.
C. Ledda (2019)
Patient-Derived Organotypic Tumor Spheroids Facilitate Precision Medicine Advances in Therapeutic Screening for Malignant Pleural Mesothelioma
Dalia Larios Chavez (2019)
Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
P. Ferro (2013)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
III Italian Consensus Conference on Malignant Mesothelioma of the Pleura. Epidemiology, Public Health and Occupational Medicine related issues.
C. Magnani (2015)
Semantic Scholar Logo Some data provided by SemanticScholar